This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (71)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

A Double-blind, Placebo Controlled Study

H. Sandvad Rasmussen, MD; Peter Aurup, MD; Karin Goldstein, MD; Peter McNair, PhD, MD; Per B. Mortensen, PhD, MD; O. G. Larsen, MD; Henrik Lawaetz, MD

Arch Intern Med. 1989;149(5):1050-1053.

Abstract
• In a double-blind, placebo-controlled study, 47 patients with ischemic heart disease and acute myocardial infarction were allocated to 3 months' treatment with peroral magnesium (15 mmol/d) or placebo. Before, during, and after treatment, blood samples were taken to determine serum concentrations of cholesterol; triglyceride; high-density, low-density, and very-low-density lipoprotein; apolipoprotein A1 and B; and magnesium. We found a 13% increase in molar ratio of apolipoprotein A1:apolipoprotein B after magnesium treatment, as compared with a 2% increase in the placebo group (for mean differences between changes of the magnesium and the placebo groups). This increase was caused by a decrease in apolipoprotein B concentrations, which were reduced by 15% from 1.44 to 1.23 mmol/L in the magnesium group as compared with a slight increase in the placebo group. Triglyceride, and thereby very-low-density lipoprotein concentrations decreased by 27% after magnesium treatment (from 2.41 to 1.76 mmol/L, and from 1.1 to 0.79 mmol/L, respectively) as compared with much smaller decrements in the placebo group. Likewise, we found tendencies toward an increase in high-density lipoprotein cholesterol and in high-density lipoprotein cholesterol ratio/(low-density lipoprotein cholesterol:very-low-density lipoprotein cholesterol) after magnesium treatment. The observed findings support the hypothesis that magnesium deficiency might be involved in the pathogenesis of ischemic heart disease by altering the blood lipid composition in a way that disposes to atherosclerosis.

(Arch Intern Med. 1989;149:1050-1053)

Author Affiliations
From the Departments of Cardiology (Drs Aurup, Larsen, and Lawaetz), Clinical Chemistry (Dr McNair), and Medical and Surgical Gastroenterology (Drs Rasmussen and Mortensen), University of Copenhagen, Hvidovre (Denmark) Hospital; and Department of Clinical Chemistry, Gentofte County Hospital, Copenhagen, Denmark (Dr Goldstein). Dr Rasmussen is now with the Pfizer Limited, Pfizer Central Research, Kent, England.

Footnotes
Accepted for publication January 11, 1989.

Reprints not available.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Serum Ionized Magnesium Levels in Relation to Metabolic Syndrome in Type 2 Diabetic Patients
Corica et al.
J. Am. Coll. Nutr. 2006;25:210-215.
ABSTRACT | FULL TEXT  

Magnesium Intake, C-Reactive Protein, and the Prevalence of Metabolic Syndrome in Middle-Aged and Older U.S. Women
Song et al.
Diabetes Care 2005;28:1438-1444.
ABSTRACT | FULL TEXT  

Magnesium Intake and Risk of Coronary Heart Disease among Men
Al-Delaimy et al.
J. Am. Coll. Nutr. 2004;23:63-70.
ABSTRACT | FULL TEXT  

Recommendations for the Outpatient Surveillance of Renal Transplant Recipients
KASISKE et al.
J. Am. Soc. Nephrol. 2000;11 :S1-S86.
ABSTRACT | FULL TEXT  

Intralymphocyte Free Magnesium in a Group of Subjects With Essential Hypertension
Delva et al.
Hypertension 1996;28:433-439.
ABSTRACT | FULL TEXT  

The Rationale of Magnesium Supplementation in Acute Myocardial Infarction: A Review of the Literature
Shechter et al.
Arch Intern Med 1992;152:2189-2196.
ABSTRACT  

Magnesium Deficiency and Diabetes
Campbell and Nadler
The Diabetes Educator 1992;18:17-19.